Carboplatin

Molecular Structure:

Molecular Formula: C₆H₁₂N₂O₄Pt
Molecular Weight: 371.2556
IUPAC Name: Azanide; cyclobutane-1,1-dicarboxylic acid; platinum
Synonyms of Carboplatin (CAS NO.41575-94-4): CCarboplatin [USAN:INN:BAN:JAN] ; 1,1-Cyclobutanedicarboxylate diammine platinum(II) ; CCRIS 3404 ; Carboplatine ; Carboplatine [French] ; Carboplatino ; Carboplatino [Spanish] ; Carboplatinum ; Carboplatinum [Latin] ; Cbdca ; Diammine(1,1-cyclobutanedicarboxylato)platinum (II) ; EINECS 255-446-0 ; HSDB 6957 ; JM 8 ; NSC 201345 ; NSC 241240 ; NSC-241240 ; Paraplatin ; Platinum(II), (1,1-cyclobutanedicarboxylato)diammine-, cis- ; UNII-BG3F62OND5 ; cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) ; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum ; Platinum, diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))-, (SP-4-2)- ; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)- ; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
CAS NO: 41575-94-4
Classification Code: Antineoplastic  Antineoplastic Agents  Cross-Linking Reagents  Drug / Therapeutic Agent  Indicators and Reagents  Mutation data  Reproductive Effect
Melting Point: 228-230 ° C 
Flash Point: 189.6 °C
Enthalpy of Vaporization: 67.31 kJ/mol
Boiling Point: 366.4 °C at 760 mmHg
Vapour Pressure: 2.27E-06 mmHg at 25°C

 Carboplatin (CAS NO.41575-94-4) was discovered and developed at the Institute of Cancer Research in London. Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. The drug went generic in October 2004. There are also generic versions of the drug available from APP Pharmaceuticals, Sicor (Teva), Bedford Laboratories,  Pharmachemie, Sandoz, Hospira,Pliva, Spectrum.

Reduced nephrotoxicity and Antineoplastic
A study in mutant mice suggests that in the subset of women with breast cancer due to BRCA1 and BRCA2 genes (these cause a variety of familial breast cancer) carboplatin may be as much as 20 times more effective than the usual breast cancer treatments.However, similar data in humans has not yet been shown.
 Carboplatin (CAS NO.41575-94-4) has also been used to treat testicular cancer patients with stage 1 seminoma. Recent research indicates that this treatment is more effective and has fewer side effects than adjuvant radiotherapy, It is as effective as radiotherapy at preventing development of seminoma in the remaining testicle.

Hazard Codes of Carboplatin (CAS NO.41575-94-4): T
Risk Statements: 46-61-20/21/22-42/43 
R46: May cause heritable genetic damage. 
R61: May cause harm to the unborn child. 
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed. 
R42/43: May cause sensitization by inhalation and skin contact.
Safety Statements: 53-22-26-36/37/39-45 
S53: Avoid exposure - obtain special instructions before use. 
S22: Do not breathe dust. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection. 
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: 2811
WGK Germany: 3